The first U.S. patient has been treated with Oxervate eye drops for neurotrophic keratitis, Dompé announced in a press release.
Oxervate (cenegermin-bkbj), a recombinant human nerve growth factor that was approved by the FDA in August 2018, has the potential to resolve neurotrophic keratitis in one 8-week treatment cycle.
“I am excited to be among the first physicians to treat neurotrophic keratitis patients with this new therapy,” Giacomina Massaro-Giordano, MD, of the Scheie Eye Institute at the University of Pennsylvania and an investigator in the Oxervate clinical trials, said in the release. “This newly approved therapy provides clinical improvements for NK patients, many of whom are at risk for losing their sight, and treatment options to help them were previously limited to symptom management.”
Oxervate is commercially available in the U.S. through Accredo specialty pharmacy. Dompé has also begun Dompé Connect to Care, a support program that provides educational resources on neurotrophic keratitis, and the Oxervate Co-pay Card Program and the Dompé Patient Assistance Program, which offer financial assistance to eligible patients, the release said.